Having trouble accessing articles? Reset your cache.

AXL1717: Interim Phase I/II data

Interim data from 35 patients in the Phase I portion of the ongoing, open-label, dose-escalation,

Read the full 151 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE